Aim: To determine whether mycophenolate mofetil (MMF) has beneficial effects on refractory idiopathic thrombocytopenic purpura (ITP) and the corresponding cellular mechanism.
Methods: Twenty refractory ITP patients resistant to corticosteroid and/or splenectomy and chemical therapy were given MMF 1.5-2.0 g/d orally for a 2 to 4-month period. Serum immunoglobulin was detected by rate nephelometry. Platelet-associated antibodies (PAIgG) were assayed by enzyme-linked immunosorbant assay. The immunophenotypic analysis was performed on a flow cytometer and cell apoptosis was detected with transferase mediated dUTP biotin nick end labeling (TUNEL) method.
Results: Sixteen of the 20 (80%) patients had responses to MMF treatment; 9 (45%) achieved a complete response, 4 (20%) achieved a partial response, and 3 (15%) achieved a minor response. The therapeutic effects were found to be better in male patients than female patients. The number of CD3+ peripheral blood cells (PBCs) and CD4+ PBCs increased and the number of CD8+ PBCs decreased. The plasma level of IgG, IgM, IgA and platelet associated IgG (PAIgG) decreased in 86% of the patients. TUNEL assay showed that mycophenolate acid (MPA) 0.1 mmol/L induced apoptosis of peripheral blood mononuclear cells isolated from refractory ITP patients. The apoptosis rate was increased in male patients after treatment with MPA, but was unchanged in female patients.
Conclusion: Therapy for a period of 8 to 16 weeks with median-dose of MMF was valuable for the treatment of refractory ITP.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/j.1745-7254.2005.00088.x | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
SARS-CoV-2 infection-induced immune thrombocytopenia in a patient with orthotopic heart transplantation: A case report and literature review.
J Cardiol Cases
December 2024
Department of Cardiovascular Medicine, Chiba University Graduate School of Medicine, Chiba, Japan.
Unlabelled: Immune thrombocytopenia (ITP) is an acquired autoimmune disorder characterized by low platelet counts with increased risk of bleeding. In particular, ITP induced by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has been increasingly reported. Since immunosuppressive regimens in organ transplantation are often the primary cause of increased risk of infection, ITP following solid organ transplantation has occasionally been observed.
View Article and Find Full Text PDFInsights on treatment of adult ITP: algorithm for management and role of multimodal therapy.
Hematology Am Soc Hematol Educ Program
December 2024
Department of Internal Medicine and Clinical Immunology, Henri Mondor University Hospital, Assistance Publique-Hôpitaux de Paris, Université Paris-Est Créteil, Créteil, France.
The management of immune thrombocytopenia (ITP) is continuously evolving with the development and introduction of newer therapies and a better understanding of the disease. Corticosteroids still represent the cornerstone of first-line treatment. Patients who fail to achieve remission with a short course of corticosteroids require subsequent therapy.
View Article and Find Full Text PDFCOVID-19-Associated Immune Thrombocytopenic Purpura in a Hemodialysis Patient.
J Blood Med
November 2024
Kidney Institute of PLA, Department of Nephrology, Shanghai Changzheng Hospital, Naval Medical University, Shanghai, People's Republic of China.
Background: Severe acute respiratory syndrome coronavirus (SARS-CoV-2) infection has been a global threat since the end of 2019. Although the main clinical manifestation of coronavirus disease 2019 (COVID-19) is respiratory, its range of clinical manifestation is extensive and may include various systems, including hematological disorders, such as lymphopenia, thrombotic events, thrombocytopenia and immune thrombocytopenic purpura (ITP). The present case was the first one that aimed to raise awareness of ITP induced by COVID-19 in patients undergoing maintenance hemodialysis.
View Article and Find Full Text PDFA case report of refractory immune thrombocytopenia: Challenges in choice of therapies in resource limiting center.
Int J Surg Case Rep
November 2024
Assistant Professor of Surgery, College of Health Science, Deberetabor University, Debretabor, Ethiopia. Electronic address:
Introduction And Importance: Refractory immune thrombocytopenic purpura (ITP) is a rare but serious condition causing significant morbidity and mortality due to inadequate response to standard treatments, resulting in persistent thrombocytopenia and increased bleeding risk.
Case Presentation: An 18-year-old female patient, diagnosed with ITP two years prior following excessive vaginal bleeding and fatigue, was initially treated with oral prednisolone for two months and discharged in improved condition. Eighteen months after treatment cessation, she presented with recurrent excessive vaginal bleeding, intermittent bilateral nasal bleeding, skin rash, blurred vision, fatigue, tinnitus, vertigo, and intermittent headaches (one-month duration).
The Many Faces of Immune Thrombocytopenia: Mechanisms, Therapies, and Clinical Challenges in Oncological Patients.
J Clin Med
November 2024
General Surgery Department, SP ZOZ in Łęczna, 21-010 Łęczna, Poland.
Unlabelled: The pathogenesis of immune thrombocytopenia (ITP) is complex and involves the dysregulation of immune cells, such as T and B lymphocytes, and several cytokines that promote the production of autoantibodies. In the context of cancer patients, ITP can occur in both primary and secondary forms related to anticancer therapies or the disease itself.
Objective: In light of these data, we decided to prepare a literature review that will explain the classification and immunological determinants of the pathogenesis of ITP and present the clinical implications of this condition, especially in patients with cancer.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!